Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Ege University, İzmir, Turkey
Department of Chest Diseases, Faculty of Medicine, Ege University, İzmir, Turkey
Turk J Med Sci. 2021 Jun 28;51(3):912-920. doi: 10.3906/sag-2008-33.
BACKGROUND/AIM: The aim of this descriptive article is to share the experience in Ege University, Turkey with favipiravir in the treatment of severe SARS-CoV-2 pneumonia.
This retrospective descriptive study included patients diagnosed with COVID-19 who presented with or developed severe pneumonia.
Forty patients who completed a full course (at least 5 days) of favipiravir were included in the study. At baseline, 30 (75%) patients required treatment for respiratory distress. Thirty-three patients (82.5%) were discharged from the hospital with full recovery, 6 patients (15%) died and 1 case (2.5%) was still at the intensive care unit (ICU) when this paper was written.
This study provides relevant information for the treatment of COVID-19, suggesting that favipiravir was associated with significant clinical and laboratory improvements in the majority of the patients, is a safe drug with no serious side effects and would merit further investigation.
背景/目的：本文旨在分享土耳其伊兹密尔大学在使用法匹拉韦治疗严重 SARS-CoV-2 肺炎方面的经验。
本回顾性描述性研究纳入了患有或发展为重症肺炎的 COVID-19 患者。
共有 40 名完成了完整疗程（至少 5 天）的法匹拉韦治疗的患者纳入本研究。基线时，30 名（75%）患者需要治疗呼吸窘迫。33 名患者（82.5%）完全康复出院，6 名患者（15%）死亡，1 名患者（2.5%）在本文撰写时仍在重症监护病房（ICU）。
本研究为 COVID-19 的治疗提供了相关信息，提示法匹拉韦可使大多数患者的临床和实验室指标显著改善，是一种安全的药物，无严重副作用，值得进一步研究。
